TSS
INMB icon

Two Sigma Securities’s INmune Bio INMB Stock Holding History

Two Sigma Securities’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,530
Closed -$16.4K – 2047
2026
Q1 		$16.4K Sell
14,530
-10,833
-43% -$15.4K ﹤0.01% 1400
2025
Q4 		$39.6K Buy
+25,363
New +$45.3K 0.01% 1104

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Securities's INMB Position: Q2 2026 in Review

Two Sigma Securities sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 14,530 shares — an estimated $16.4K sold.

Two Sigma Securities first reported a position in INMB in Q4 2025 and held it in 2 quarters. The position peaked at $39.6K in Q4 2025. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Two Sigma Securities reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 14,530 INmune Bio shares in Q2 2026, an estimated $16.4K.
  • Two Sigma Securities first reported a position in INmune Bio in Q4 2025 and held it in 2 quarters.
  • Two Sigma Securities's INmune Bio position peaked at $39.6K in Q4 2025.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.